[Probability of the combination use of cisplatin and carboplatin].

Nihon Gan Chiryo Gakkai shi Pub Date : 1990-11-20
K Kobayashi, M Hino, K Hayashihara, H Niitani
{"title":"[Probability of the combination use of cisplatin and carboplatin].","authors":"K Kobayashi,&nbsp;M Hino,&nbsp;K Hayashihara,&nbsp;H Niitani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>To investigate whether each of cisplatin (CDDP) and carboplatin (CBDCA) was AUC (Area Under the Curve)-dependent or time-dependent drug, Human Tumor Clonogenic Assays (HTCA) were performed in various exposure times of CDDP or CBDCA using PC-9 cells. From the result of this study, it was shown that CDDP and CBDCA were AUC dependent drugs. Furthermore, to evaluate the combination effect of CDDP and CBDCA, we carried out HTCA using PC-9 and PC-14 (human lung adenocarcinoma cell lines) cells, and evaluated the combination effect by the median effect analysis of Chou, T.C. and Talalay, P. The combination effects were above the additive effects at the AUC ratios of free Pt in the exposure medium of 3.2, 6.5, 13.1 (CBDCA/CDDP). Especially in the combination of 3 hours exposure of CBDCA followed by 1 hour exposure of CDDP, the Combination Index by median effect analysis was from 0.74 to 0.86 at the AUC ratio of 13.1. But the combination effect was antagonistic at that of 19.5. CDDP and CBDCA, which are AUC dependent drugs, have shown different side effects in previous clinical practice. And the combination effect of both drugs is more than additive effect at the AUC ratios of free Pt of 3.2, 6.5, 13.1 (CBDCA/CDDP). It is considered that the combination chemotherapy of CDDP and CBDCA for patients of lung adenocarcinoma may be useful.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 11","pages":"2684-92"},"PeriodicalIF":0.0000,"publicationDate":"1990-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Gan Chiryo Gakkai shi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To investigate whether each of cisplatin (CDDP) and carboplatin (CBDCA) was AUC (Area Under the Curve)-dependent or time-dependent drug, Human Tumor Clonogenic Assays (HTCA) were performed in various exposure times of CDDP or CBDCA using PC-9 cells. From the result of this study, it was shown that CDDP and CBDCA were AUC dependent drugs. Furthermore, to evaluate the combination effect of CDDP and CBDCA, we carried out HTCA using PC-9 and PC-14 (human lung adenocarcinoma cell lines) cells, and evaluated the combination effect by the median effect analysis of Chou, T.C. and Talalay, P. The combination effects were above the additive effects at the AUC ratios of free Pt in the exposure medium of 3.2, 6.5, 13.1 (CBDCA/CDDP). Especially in the combination of 3 hours exposure of CBDCA followed by 1 hour exposure of CDDP, the Combination Index by median effect analysis was from 0.74 to 0.86 at the AUC ratio of 13.1. But the combination effect was antagonistic at that of 19.5. CDDP and CBDCA, which are AUC dependent drugs, have shown different side effects in previous clinical practice. And the combination effect of both drugs is more than additive effect at the AUC ratios of free Pt of 3.2, 6.5, 13.1 (CBDCA/CDDP). It is considered that the combination chemotherapy of CDDP and CBDCA for patients of lung adenocarcinoma may be useful.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[顺铂与卡铂联合使用的概率]。
为了研究顺铂(CDDP)和卡铂(CBDCA)是AUC(曲线下面积)依赖性药物还是时间依赖性药物,使用PC-9细胞在CDDP或CBDCA的不同暴露时间下进行了人类肿瘤克隆测定(HTCA)。本研究结果表明,CDDP和CBDCA均为AUC依赖性药物。此外,为了评价CDDP和CBDCA的联合效应,我们使用PC-9和PC-14(人肺腺癌细胞系)细胞进行HTCA,并通过Chou, T.C.和Talalay, P.的中位效应分析来评价联合效应。在暴露介质中游离Pt的AUC比为3.2,6.5,13.1 (CBDCA/CDDP)时,联合效应高于加性效应。特别是在CBDCA暴露3小时后,CDDP暴露1小时的组合,中位效应分析的组合指数在0.74 ~ 0.86之间,AUC比为13.1。联合效应为拮抗效应,为19.5倍。CDDP和CBDCA作为AUC依赖药物,在以往的临床实践中表现出不同的副作用。游离Pt AUC比分别为3.2、6.5、13.1 (CBDCA/CDDP)时,两药联合作用大于加性作用。认为CDDP与CBDCA联合化疗对肺腺癌患者可能是有益的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Chemoembolization therapy with lipiodol, cisplatin and etoposide for hepatocellular carcinoma]. [Relationship between human papillomavirus and oncogenes (c-myc, N-myc) amplification in human cervical cancers]. [Treatment of liver metastatic ovarian cancer with sequential administration of OK-432 and etoposide]. Flow cytometric analysis of nuclear DNA content in patients with recurrent epithelial ovarian cancer. [The effect on prognosis and the adverse drug reaction of intermittent cisplatin therapy in advanced ovarian cancer patients].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1